[
  {
    "title": "The past three years for Incyte (NASDAQ:INCY) investors has not been profitable",
    "published": 1713186886,
    "posting_price": 53.90999985,
    "close_price": 53.43000031,
    "percent_change": -0.89037199
  },
  {
    "title": "Certain\u00a0Biotech Investors Get an Early Look at Results. Is That Fair?",
    "published": 1713173400,
    "posting_price": 53.90999985,
    "close_price": 53.43000031,
    "percent_change": -0.89037199
  },
  {
    "title": "Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings",
    "published": 1712926811,
    "posting_price": 54.72000122,
    "close_price": 53.84999847,
    "percent_change": -1.58991727
  },
  {
    "title": "Incyte Corp. stock outperforms competitors despite losses on the day",
    "published": 1712895660,
    "posting_price": 54.72000122,
    "close_price": 53.84999847,
    "percent_change": -1.58991727
  },
  {
    "title": "Incyte to Report First Quarter Financial Results",
    "published": 1712836800,
    "posting_price": 55.34000015,
    "close_price": 54.91999817,
    "percent_change": -0.75894828
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)",
    "published": 1712569260,
    "posting_price": 54.97000122,
    "close_price": 55.04999924,
    "percent_change": 0.14553032
  },
  {
    "title": "Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion",
    "published": 1712471400,
    "posting_price": 54.97000122,
    "close_price": 55.04999924,
    "percent_change": 0.14553032
  },
  {
    "title": "Biotech Executive Who Bet on Rival\u2019s Stock Committed Insider Trading, Jury Says",
    "published": 1712408160,
    "posting_price": 54.97000122,
    "close_price": 55.04999924,
    "percent_change": 0.14553032
  },
  {
    "title": "Jury sides with SEC in trial over insider trading charges against former pharma executive",
    "published": 1712401200,
    "posting_price": 54.97000122,
    "close_price": 55.04999924,
    "percent_change": 0.14553032
  },
  {
    "title": "Top buy-rated stocks and sell-rated stocks within Health Care - Citi",
    "published": 1712225880,
    "posting_price": 55.54999924,
    "close_price": 54.99000168,
    "percent_change": -1.00809643
  },
  {
    "title": "Incyte Corp. stock underperforms Wednesday when compared to competitors",
    "published": 1712118120,
    "posting_price": 55.84000015,
    "close_price": 55.31000137,
    "percent_change": -0.94913821
  },
  {
    "title": "Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates",
    "published": 1714492200,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte misses quarterly profit on weak sales of lead drug",
    "published": 1714486208,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "published": 1714483825,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in ...",
    "published": 1714480467,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript",
    "published": 1714477382,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)",
    "published": 1714477260,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs",
    "published": 1714474800,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024",
    "published": 1714474740,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte Corporation 2024 Q1 - Results - Earnings Call Presentation",
    "published": 1714464689,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte: Q1 Earnings Snapshot",
    "published": 1714461075,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte  sees FY24 Jakafi net product revenue $2.7B-$2.8B",
    "published": 1714459140,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte reports Q1 EPS 64c, consensus 84c",
    "published": 1714458960,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M",
    "published": 1714457160,
    "posting_price": 50.40000153,
    "close_price": 52.04999924,
    "percent_change": 3.27380488
  },
  {
    "title": "Incyte Q1 2024 Earnings Preview",
    "published": 1714387800,
    "posting_price": 51.75,
    "close_price": 52.56000137,
    "percent_change": 1.56522004
  },
  {
    "title": "Notable earnings before Tuesday's open",
    "published": 1714386060,
    "posting_price": 51.75,
    "close_price": 52.56000137,
    "percent_change": 1.56522004
  },
  {
    "title": "Truist Financial Reaffirms Their Buy Rating on Incyte (INCY)",
    "published": 1714373580,
    "posting_price": 51.75,
    "close_price": 52.56000137,
    "percent_change": 1.56522004
  },
  {
    "title": "'Shadow Trading' Verdict A Reminder For Companies To Review Insider Trading Policies And Train Insiders",
    "published": 1714371010,
    "posting_price": 51.75,
    "close_price": 52.56000137,
    "percent_change": 1.56522004
  },
  {
    "title": "Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)",
    "published": 1714139112,
    "posting_price": 50.99000168,
    "close_price": 51.68000031,
    "percent_change": 1.35320378
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals",
    "published": 1714134300,
    "posting_price": 50.99000168,
    "close_price": 51.68000031,
    "percent_change": 1.35320378
  },
  {
    "title": "Repare Therapeutics appoints Steven Stein to its board of directors",
    "published": 1714101660,
    "posting_price": 50.99000168,
    "close_price": 51.68000031,
    "percent_change": 1.35320378
  },
  {
    "title": "Incyte\u2019s Strategic Acquisition and Promising Pipeline Secure Buy Rating",
    "published": 1714094220,
    "posting_price": 50.99000168,
    "close_price": 51.68000031,
    "percent_change": 1.35320378
  },
  {
    "title": "Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX",
    "published": 1714069680,
    "posting_price": 51.58000183,
    "close_price": 51.18000031,
    "percent_change": -0.7754973
  },
  {
    "title": "These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)",
    "published": 1714067356,
    "posting_price": 51.58000183,
    "close_price": 51.18000031,
    "percent_change": -0.7754973
  },
  {
    "title": "Incyte price target lowered by $10 at Argus, here's why",
    "published": 1714033680,
    "posting_price": 51.58000183,
    "close_price": 51.18000031,
    "percent_change": -0.7754973
  },
  {
    "title": "Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?",
    "published": 1713967300,
    "posting_price": 51.65000153,
    "close_price": 51.74000168,
    "percent_change": 0.17425004
  },
  {
    "title": "\"Shadow Trading\" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case",
    "published": 1713960673,
    "posting_price": 51.65000153,
    "close_price": 51.74000168,
    "percent_change": 0.17425004
  },
  {
    "title": "Incyte price target lowered by $8 at Oppenheimer, here's why",
    "published": 1713941820,
    "posting_price": 51.65000153,
    "close_price": 51.74000168,
    "percent_change": 0.17425004
  },
  {
    "title": "Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)",
    "published": 1713941220,
    "posting_price": 51.65000153,
    "close_price": 51.74000168,
    "percent_change": 0.17425004
  },
  {
    "title": "Truist Financial Keeps Their Buy Rating on Incyte (INCY)",
    "published": 1713939480,
    "posting_price": 51.65000153,
    "close_price": 51.74000168,
    "percent_change": 0.17425004
  },
  {
    "title": "Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation",
    "published": 1713933360,
    "posting_price": 51.65000153,
    "close_price": 51.74000168,
    "percent_change": 0.17425004
  },
  {
    "title": "Incyte (INCY) Earnings Expected to Grow: Should You Buy?",
    "published": 1713880863,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte (INCY) to Report Q1 Earnings: What's in the Cards?",
    "published": 1713879840,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Peeling Back The Layers: Exploring Incyte Through Analyst Insights",
    "published": 1713873900,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists",
    "published": 1713870000,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls",
    "published": 1713865020,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte to acquire immune-focused drug developer Escient",
    "published": 1713854280,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte to acquire Escient Pharmaceuticals for $750M",
    "published": 1713852960,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte initiated with a Neutral at Cantor on 'lukewarm view' of pipeline",
    "published": 1713852480,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte\u2019s Strategic Acquisition: A Premature and Costly Move Amid Patent Cliff Concerns",
    "published": 1713852360,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte initiated with neutral view at Cantor Fitzgerald",
    "published": 1713849180,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte (INCY) Gets a Buy from Piper Sandler",
    "published": 1713839160,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Piper likes Incyte's Escient acquisition, looking for more deals",
    "published": 1713838380,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends",
    "published": 1713837960,
    "posting_price": 52.0,
    "close_price": 51.65000153,
    "percent_change": -0.67307398
  },
  {
    "title": "Top high growth investment ratio stocks from each sector - GS",
    "published": 1713756360,
    "posting_price": 52.43000031,
    "close_price": 51.91999817,
    "percent_change": -0.97272961
  },
  {
    "title": "Goldman picks top capex and R&D stocks",
    "published": 1713663840,
    "posting_price": 52.43000031,
    "close_price": 51.91999817,
    "percent_change": -0.97272961
  },
  {
    "title": "Top 10 most oversold S&P 500 stocks",
    "published": 1713524580,
    "posting_price": 52.97000122,
    "close_price": 52.34999847,
    "percent_change": -1.17047902
  }
]